2024-09-04 - Analysis Report
##  ABBV Stock Analysis Report

This report provides a comprehensive analysis of AbbVie Inc. (ABBV) based on the provided data.

**1.  Performance Comparison:**

* **Company Overview:** AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and markets a range of pharmaceutical products, including Humira, a leading treatment for autoimmune diseases.
* **Performance:**  ABBV's cumulative return is **106.38%**, exceeding the S&P 500 (VOO) by **16.72%** (cumulative return: **89.66%**). This outperformance is notable, representing a **65.53%** position within the historical range of their performance difference. 

**2.  Recent Price Action:**

* **Closing Price:** $196.31
* **5-day Moving Average:** $196.05
* **20-day Moving Average:** $193.17
* **60-day Moving Average:** $179.48

The current price is slightly above the 5-day moving average, indicating potential short-term upward momentum. The price is also comfortably above both the 20-day and 60-day moving averages, suggesting a healthy upward trend in the medium to long term. 

**3.  Technical Indicators:**

* **RSI:** 74.27 - The Relative Strength Index (RSI) is above 70, suggesting the stock is in overbought territory. This could indicate potential for a short-term correction.
* **PPO:** -0.36 - The Percentage Price Oscillator (PPO) is negative, indicating a potential slowdown in the stock's momentum. 
* **Delta_Previous_Relative_Divergence:** -3.27 - The recent (20-day) relative divergence is negative, suggesting a potential short-term downward trend.
* **Expected Return:** 16.29% -  This represents the potential maximum return over a 5-year period, based on the current investment amount. 

**4.  Recent Earnings and Outlook:**

| Date    | EPS    | Expected EPS |
|---------|--------|--------------|
| 2024-07-25 | 2.65 | 2.57        |
| 2024-04-26 | 2.31 | 2.26        |
| 2024-02-02 | 2.79 | 2.76        |
| 2023-10-27 | 2.95 | 2.86        |
| 2023-07-27 | 2.91 | 2.79        |

The most recent earnings report (2024-07-25) shows a positive EPS beat of 0.08, outperforming analyst expectations. This performance reflects continued strong demand for AbbVie's products, particularly Humira.

**5.  Overall Analysis:**

ABBV has consistently outperformed the S&P 500, with a current outperformance of over 16%. Its recent price action indicates potential for continued upward momentum. However, technical indicators suggest potential for short-term correction due to overbought conditions and slowing momentum. Despite the potential for short-term volatility, ABBV's strong earnings performance and long-term growth potential make it a potentially attractive investment.  

**6.  Recommendations:**

Investors should consider the following:

* **Short-term:** Given the overbought conditions and potential for short-term correction, investors may consider a cautious approach and wait for a potential pullback. 
* **Long-term:**  Given ABBV's strong track record, promising product pipeline, and healthy expected return, long-term investors may find this a worthwhile opportunity to maintain a position in their portfolio. 

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. It is essential to conduct your own research and consult with a qualified financial advisor before making any investment decisions. 
